A large epidemiological study corroborated previous evidence that rates of both cognitive and behavioral impairment are high in people with amyotrophic lateral sclerosis.
Tau Takes Center Stage at 10th Human Amyloid Imaging Conference Tau Tracers Track First Emergence of Tangles in Familial Alzheimer’s Shaky Specificity of Tau PET Ligands Stokes Debate at HAI At HAI, Researchers Explore Diagnostic Potential of a Tau Tracer ...
Using PET, researchers are trying to match tau spread against structural and functional defects.
TREM2 levels tracked with tau, but varied widely among patients and carriers of different mutations, leaving it unclear whether TREM2 helps or hurts.
Aβ hijacks the neuron’s internal mechanism of synaptic plasticity to tip the balance toward long-term depression. Results suggest a new role for a tumor suppressor protein.
Lou Gehrig’s — a name given for good reason? A study supports a correlation between sports and ALS, but it is far from the final word.
Alzforum spoke with UCSD’s incoming leader for Alzheimer’s research. Where does he want to take the Alzheimer’s Disease Cooperative Study and neurodegeneration research in La Jolla and beyond?
An immunotherapy drug recruits immune cells to the brain, where they help clean up amyloid plaques.
With the most widespread chronic traumatic encephalopathy yet seen in a player that young, the 25-year-old represents the first published case with neuropsychological data.
Gene expression analysis highlights differences from mouse astrocytes as well as from immature and cultured human astrocytes.
The prion concept continues to infiltrate the neurodegeneration field, with models of SOD1 propagation and a bevy of tau strains.
The modified stem cells might slow disease, too, though the trial was too small to say for sure.
Atomic-level analysis of the protein’s C-terminal end suggests a floppy region key for the delicate process of forming functional oligomers. Mutate it slightly, and it becomes an aggregating machine.
The FTC imposed a $2 million fine on Lumos Labs for overstating the benefits of the company’s Lumosity brain-training software.
The drug benefits some patients with mild amyotrophic lateral sclerosis, and is approved in Japan.
No filters selected